# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.
Maxim Group analyst Jason McCarthy maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $45...
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects AnnAraC has po...
Summary of Financial Results for the Full Year 2023Research and development (R&D) expenses were $19.5 million and $19.0 mil...